Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of itacitinib plus corticosteroids versus placebo plus corticosteroids for first-line acute graft-versus-host disease
2017-000538-78Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Acute Graft-Versus-Host Disease (aGvHD) comparing Itacitinib + corticosteroids with Placebo + corticosteroids (2 arms). Primary endpoint: Overall response rate at Day 28. Started Jul 2017; status: terminated.
02
Drugs
itacitinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2017-000538-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000538-78.